ArticleScientific reports2025
Distinct potency of compounds targeting the T1R3 subunit in modulating the response of human sweet and umami taste receptors.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The heterodimeric G-protein-coupled receptors T1R2/T1R3 and T1R1/T1R3 have been identified as sweet and umami taste receptors, respectively, and both of these receptors share the T1R3 subunit. Previous research has indirectly indicated functional differences in the T1R3 subunit between the receptors. In this study, a comparative analysis was conducted on the responses of these receptors to substances acting on T1R3, standardizing the response measurement conditions for both. The results revealed significant differences in the modulatory effects of negative allosteric modulators (NAMs) and positive allosteric modulators (PAMs), that act on the transmembrane region of T1R3. Notably, (±)-lactisole, (±)-2,4-DP, and clofibric acid, which are sweet taste receptor inhibitors, also function as umami taste receptor inhibitors, albeit at concentrations approximately 6-10 times greater than those required for sweet taste inhibition. Additionally, cyclamate and NHDC, which are ago-PAMs of sweet taste receptors, did not activate the umami taste receptor at any concentration that significantly elicited sweet taste receptor responses. These results suggest that the binding modes of the substances to the T1R3 subunit of the sweet taste receptor and umami taste receptor are not entirely identical. The difference in the heterodimeric partners to T1R3 may account for their distinct modulation patterns of receptor function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.